"Folic Acid" a Tumor Growth Inhibitor.

Leuchtenberger, Cecilie; Lewisohn, Richard; László, Dániel; Leuchtenberger, Rudolf

doi:10.3181/00379727-55-14520

Cited by 50 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the approaches in cancer chemo therapy has been the administration of nu tritional factors, either as the only form of therapy [4,5], or more commonly in com bination with antimetabolite therapy [6). This approach led to the use of leucovorin (folinic acid) as a 'rescue' after high-dose MTX treatment.…”

Section: Introductionmentioning

confidence: 99%

Combination of Anticancer Agents with Folic Acid in the Treatment of Murine Leukaemia P388

Parchure¹,

Ambaye²,

Gokhale³

1984

Chemotherapy

View full text Add to dashboard Cite

Folic acid (FA) was combined with anticancer agents such as (i) antimetabolites like methotrexate (MTX), 5-fluorouracil (5-FU), arabinosyl cytosine (Ara-C) and 6-mercaptopurine (6-MP); (ii) plant-derived mitotic inhibitor, vincristine (VCR), and (iii) an antibiotic, mitomycin C (Mit-C). This combination modality was used for the treatment of P388 lymphocytic leukaemia. Large doses of FA were administered to the tumour-bearing mice either prior to or simultaneously with different anticancer agents. Pre-treatment with FA significantly improved the therapeutic efficacy of 5-FU, Ara-C and Mit-C; while MTX was more effective when given simultaneously with FA. The efficacy of 6-MP and VCR was not enhanced by FA when tested similarly. Large doses of FA can potentiate the activity of certain anticancer agents when administered to P388-bearing mice at critical times that vary according to the particular drug used.

show abstract

Section: Introductionmentioning

confidence: 99%

Combination of Anticancer Agents with Folic Acid in the Treatment of Murine Leukaemia P388

Parchure¹,

Ambaye²,

Gokhale³

1984

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Starting from the observation that folic acid can block the growth of tumours [114], MTX was developed as a cytostatic folic acid analogue [72]. Methotrexate blocks the formation of tetrahydrofolic acid because of its high affinity for dihydrofolic acid reductase, a co-enzyme for C1-metabolism during the synthesis of nucleic acid.…”

Section: Cytostaticsmentioning

confidence: 99%

Systemic therapy strategies for head-neck carcinomas: Current status

Hoffmann¹

2012

GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery; 11:Doc03; ISSN 1865-1011

View full text Add to dashboard Cite

“…At the time of the work on anti‐metabolites, it was apparent that folic acid was essential for cell growth and formation of blood. Leuchtenberger et al (1944) postulated that folic acid might be able to mature other cells, such as malignant cells, and this led to trials to see if folic acid might be useful in the treatment of leukaemia. Folic acid was first synthesised in 1945 (Angier et al , 1945) and several people began using it in patients with acute leukaemia.…”

Section: Diagnoses and Number Of Patients Treated With 6‐mercaptopurmentioning

confidence: 99%

Joe Burchenal and the birth of combination chemotherapy

Thomas

2006

Br J Haematol

View full text Add to dashboard Cite

SummaryWhen Joe Burchenal started studying medicine at the University of Pennsylvania in 1934, antibiotics had not been discovered and the survival of patients diagnosed with acute leukaemia was <4 months. By the time he retired in 1983, 58% of children with acute lymphoblastic leukaemia survived 5 years with the majority being cured of their disease. His early work in infectious diseases and antimicrobials equipped him well, both clinically and scientifically. The approach to developing antibiotics to conquer previously incurable infection was an inspiration and model for his pioneering work when searching for drugs with activity against cancer. Trials of sequential and then combination chemotherapy followed. Success in treating lymphoid malignancies in children led him to develop treatment regimens for other more resistant cancers, and as an advocate of collaborative working he introduced multimodal therapy to tackle bulky or metastatic cancers, replacing inevitable relapse with a chance of true cure.

show abstract

"Folic Acid" a Tumor Growth Inhibitor.

Cited by 50 publications

References 0 publications

Combination of Anticancer Agents with Folic Acid in the Treatment of Murine Leukaemia P388

Combination of Anticancer Agents with Folic Acid in the Treatment of Murine Leukaemia P388

Systemic therapy strategies for head-neck carcinomas: Current status

Joe Burchenal and the birth of combination chemotherapy

Contact Info

Product

Resources

About